- Home
- SKYH vs CANF Comparison
SKYH vs CANF Comparison
Compare SKYH & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYH | CANF |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 4.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | SKYH | CANF |
|---|---|---|
| Price | $9.66 | $3.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $13.83 | ★ $9,750.00 |
| AVG Volume (30 Days) | 103.0K | ★ 607.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $95.29 | $461.72 |
| Revenue Next Year | $69.22 | $290,391.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.22 | $0.17 |
| 52 Week High | $14.20 | $10.40 |
Technical Indicators
Market Signals| Indicator | SKYH | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 38.43 |
| Support Level | $9.55 | $0.60 |
| Resistance Level | $10.69 | $4.74 |
| Average True Range (ATR) | 0.31 | 0.66 |
| MACD | 0.06 | -0.19 |
| Stochastic Oscillator | 90.29 | 1.27 |
Price Performance
Historical ComparisonAbout SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.